Vanguard Personalized Indexing Management LLC Purchases 17,956 Shares of Colgate-Palmolive Company $CL

Key Points

• Vanguard Personalized Indexing Management LLC has increased its stake in Colgate-Palmolive by 17.8%, acquiring an additional 17,956 shares, bringing its total holdings to 118,665 shares valued at approximately $10.79 million.
• Colgate-Palmolive Company reported earnings of $0.92 EPS for the last quarter, exceeding analysts' expectations of $0.89, with revenues reaching $5.11 billion.
• The company declared a quarterly dividend of $0.52, with an ex-dividend date of October 17th, representing a 2.7% yield based on its current stock price.

Vanguard Personalized Indexing Management LLC lifted its position in Colgate-Palmolive Company (NYSE:CL - Free Report) by 17.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 118,665 shares of the company's stock after acquiring an additional 17,956 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Colgate-Palmolive were worth $10,791,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CL. Brighton Jones LLC raised its position in shares of Colgate-Palmolive by 4.4% in the 4th quarter. Brighton Jones LLC now owns 10,578 shares of the company's stock worth $962,000 after acquiring an additional 450 shares in the last quarter. GAMMA Investing LLC increased its position in Colgate-Palmolive by 14.2% during the 1st quarter. GAMMA Investing LLC now owns 11,797 shares of the company's stock valued at $1,105,000 after buying an additional 1,468 shares in the last quarter. NorthCrest Asset Manangement LLC increased its position in Colgate-Palmolive by 65.8% during the 1st quarter. NorthCrest Asset Manangement LLC now owns 3,329 shares of the company's stock valued at $312,000 after buying an additional 1,321 shares in the last quarter. Elevation Point Wealth Partners LLC increased its position in Colgate-Palmolive by 8.3% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 3,572 shares of the company's stock valued at $335,000 after buying an additional 273 shares in the last quarter. Finally, CVA Family Office LLC increased its position in Colgate-Palmolive by 5.9% during the 1st quarter. CVA Family Office LLC now owns 3,219 shares of the company's stock valued at $302,000 after buying an additional 179 shares in the last quarter. Institutional investors own 80.41% of the company's stock.

Colgate-Palmolive Stock Performance

CL stock opened at $77.99 on Monday. The company has a market cap of $63.03 billion, a P/E ratio of 21.91, a price-to-earnings-growth ratio of 4.29 and a beta of 0.34. Colgate-Palmolive Company has a 1 year low of $77.09 and a 1 year high of $102.61. The company has a debt-to-equity ratio of 6.79, a current ratio of 0.89 and a quick ratio of 0.57. The stock's fifty day moving average price is $82.56 and its 200-day moving average price is $87.84.

Colgate-Palmolive (NYSE:CL - Get Free Report) last announced its earnings results on Friday, August 1st. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.03. Colgate-Palmolive had a return on equity of 377.63% and a net margin of 14.55%.The company had revenue of $5.11 billion for the quarter, compared to analysts' expectations of $5.03 billion. During the same period last year, the firm earned $0.91 EPS. Colgate-Palmolive's revenue for the quarter was up 1.0% compared to the same quarter last year. On average, equities analysts forecast that Colgate-Palmolive Company will post 3.75 earnings per share for the current year.

Colgate-Palmolive Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Friday, October 17th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, October 17th. Colgate-Palmolive's payout ratio is presently 58.43%.

Analyst Ratings Changes

A number of research firms recently weighed in on CL. Barclays reduced their price objective on Colgate-Palmolive from $87.00 to $82.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 1st. UBS Group reduced their price objective on Colgate-Palmolive from $99.00 to $92.00 and set a "buy" rating for the company in a research report on Wednesday. Bank of America reduced their price objective on Colgate-Palmolive from $98.00 to $88.00 and set a "buy" rating for the company in a research report on Wednesday, October 8th. Piper Sandler began coverage on Colgate-Palmolive in a research report on Friday, October 3rd. They set a "neutral" rating and a $84.00 price objective for the company. Finally, Morgan Stanley reduced their price objective on Colgate-Palmolive from $104.00 to $96.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $92.21.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.